PMID- 22698379
OWN - NLM
STAT- MEDLINE
DCOM- 20121120
LR  - 20181201
IS  - 1532-2688 (Electronic)
IS  - 1059-1311 (Linking)
VI  - 21
IP  - 7
DP  - 2012 Sep
TI  - Clinical experience with oral lacosamide as adjunctive therapy in adult patients 
      with uncontrolled epilepsy: a multicentre study in epilepsy clinics in the United 
      Kingdom (UK).
PG  - 512-7
LID - 10.1016/j.seizure.2012.05.005 [doi]
AB  - INTRODUCTION: Lacosamide (LCS) is a new antiepileptic drug (AED) licensed in the 
      European Union (EU) and United States (US) in 2008. AIMS: To evaluate the 
      efficacy and tolerability of add-on LCS in an out-patient epilepsy clinic setting 
      to obtain useful information for everyday practice. METHODS: We pooled data 
      retrospectively from the case note of patients with refractory epilepsy in whom 
      LCS had been prescribed in 19 hospitals across the United Kingdom. RESULTS: Four 
      hundred and three patients were included (mean age 41.9 years, 50.6% women, 18.1% 
      with learning disabilities (LD)). Mean follow-up (FU) was 11.6 months (range one 
      day to 42 months). Most patients (86.9%) presented with symptomatic partial 
      epilepsy (SPE) and 80% were taking two or more antiepileptic drugs (AEDs) when 
      LCS was added (mean 2, range 0-4). Retention rates were 80% at six months, 68% at 
      one year and 45% at two years. The efficacy of LCS was evaluated at three months 
      and at the final FU. At three months one hundred and eight patients (31.1%) 
      reported >/= 50% seizure reduction and 32 (9.2%) were seizure free. At the final FU 
      102 (37.5%) reported >/= 50% seizures reduction and 28 (9.8%) were seizure free. 
      One hundred and ninety three patients (48.7%) reported adverse effects (AEs). The 
      most frequent were sedation and dizziness, followed by nausea. Lacosamide was 
      discontinued in 150 patients (38%), 60 due to AEs alone. CONCLUSION: LCS appears 
      to be an effective and safe AED when used as adjunctive therapy in patients with 
      refractory partial epilepsy.
CI  - Copyright (c) 2012 British Epilepsy Association. Published by Elsevier Ltd. All 
      rights reserved.
FAU - Flores, Lorena
AU  - Flores L
AD  - Department of Clinical Neurosciences, King's College Hospital NHS Foundation 
      Trust, London SE5 9RS, UK.
FAU - Kemp, Steven
AU  - Kemp S
FAU - Colbeck, Katie
AU  - Colbeck K
FAU - Moran, Nicholas
AU  - Moran N
FAU - Quirk, Jennifer
AU  - Quirk J
FAU - Ramkolea, Pierre
AU  - Ramkolea P
FAU - von Oertzen, Tim J
AU  - von Oertzen TJ
FAU - Nashef, Lina
AU  - Nashef L
FAU - Richardson, Mark P
AU  - Richardson MP
FAU - Goulding, Peter
AU  - Goulding P
FAU - Elwes, Robert
AU  - Elwes R
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20120612
PL  - England
TA  - Seizure
JT  - Seizure
JID - 9306979
RN  - 0 (Acetamides)
RN  - 0 (Anticonvulsants)
RN  - 563KS2PQY5 (Lacosamide)
SB  - IM
MH  - Acetamides/*administration & dosage/adverse effects
MH  - Administration, Oral
MH  - Adult
MH  - Anticonvulsants/*administration & dosage/adverse effects
MH  - Drug Therapy, Combination
MH  - Epilepsy/*drug therapy
MH  - Female
MH  - Humans
MH  - Lacosamide
MH  - Male
MH  - Retrospective Studies
EDAT- 2012/06/16 06:00
MHDA- 2012/12/10 06:00
CRDT- 2012/06/16 06:00
PHST- 2012/02/17 00:00 [received]
PHST- 2012/05/14 00:00 [revised]
PHST- 2012/05/15 00:00 [accepted]
PHST- 2012/06/16 06:00 [entrez]
PHST- 2012/06/16 06:00 [pubmed]
PHST- 2012/12/10 06:00 [medline]
AID - S1059-1311(12)00121-5 [pii]
AID - 10.1016/j.seizure.2012.05.005 [doi]
PST - ppublish
SO  - Seizure. 2012 Sep;21(7):512-7. doi: 10.1016/j.seizure.2012.05.005. Epub 2012 Jun 
      12.